home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biodesix, Inc. - Common Stock (NQ:BDSX)

10.63 -0.95 (-8.20%)

Streaming Delayed Price Updated: 2:57 PM EDT, Apr 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biodesix, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022

February 22, 2022

From Biodesix, Inc.

Via Business Wire

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue (Unaudited)

February 14, 2022

From Biodesix, Inc.

Via Business Wire

Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 09, 2022

From Biodesix, Inc.

Via Business Wire

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

64 Biggest Movers From Yesterday ↗

February 01, 2022

Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a...

Via Benzinga

PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics

January 19, 2022

From PierianDx

Via Business Wire

Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results

January 18, 2022

From Biodesix, Inc.

Via Business Wire

Insider Weekends: Co-Founder Of EverQuote Acquires $1.45 Million Worth Of Stock ↗

January 09, 2022

Reviewing the list of companies that were at a new 52 week high and the ones that had hit a fresh 52 week low last week, I was struck by just how many of the companies in the 52...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

Biodesix Strengthens Financial Position with Equity Issuance and Amendment to Term Loan

January 04, 2022

From Biodesix, Inc.

Via Business Wire

40 Biggest Movers From Friday ↗

January 03, 2022

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...

Via Benzinga

4 Penny Stocks Insiders Are Buying ↗

December 23, 2021

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste...

Via Benzinga

Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

December 08, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study Assessing the Clinical Effectiveness of VeriStrat® Proteomic Test in the Journal of Immunotherapy of Cancer

November 18, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix Partners with Spesana to Streamline Digital Access to Molecular Diagnostics for Precision Medicine in Lung Cancer

December 01, 2021

From Biodesix

Via Business Wire

Biodesix, Inc. (BDSX) Q3 2021 Earnings Call Transcript ↗

November 16, 2021

BDSX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Biodesix Announces Third Quarter 2021 Results and Highlights

November 15, 2021

From Biodesix, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗

November 17, 2021

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:

Via Benzinga

Biodesix to Present Data Supporting Proteomic-Based Immunotherapy Diagnostic Tests and AI Explainability in Diagnostic Tests at Society for Immunotherapy of Cancer Annual Meeting

November 12, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

November 11, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021

November 01, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix Announces New Data on Nodify Lung® Nodule Risk Assessment Testing at the CHEST 2021 Annual Meeting

October 13, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix's Return On Capital Employed Insights ↗

September 22, 2021

Biodesix (NASDAQ:BDSX) brought in sales totaling $11.88 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 89.63%, resulting in a loss of $...

Via Benzinga

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

September 16, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

September 02, 2021

From Biodesix, Inc.

Via Business Wire

Biodesix DeSoto Laboratory Receives both ISO 13485:2016 Certification and Accreditation from the College of American Pathologists

August 25, 2021

From Biodesix, Inc.

Via Business Wire

4 Stocks Insiders Are Buying ↗

August 24, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 18, 2021

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND...

Via Benzinga

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗

August 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com